Home › Multiple Sclerosis › NCT06276634

Intermittent Hypoxia in Persons With Multiple Sclerosis

Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
* Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
* Motor Functional System Scale (FSS) between 2-4
* Relapse free for at least 1 year
* Age ≥ 18 years and ≤ 75 years
* Safe to be scanned based on MRI questionnaire
* Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening

Exclusion Criteria:

* Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
* Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
* History of epilepsy
* Chronic obstructive pulmonary disease
* Uncontrolled Sleep apnea
* Pregnancy

About the study

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

What is being tested

• Acute Intermittent Hypoxia (other)
• Sham-Acute Intermittent Hypoxia (other)

Sponsor: Shirley Ryan AbilityLab · Participants: 21 · Started: Apr 30, 2024

Contact the study team

• Alexander Barry, MS, CCRC · Phone: 3122381435

Official record on ClinicalTrials.gov — NCT06276634

Locations in the U.S.

Conditions

• Multiple Sclerosis
• Relapsing-Remitting Multiple Sclerosis
• Chronic Progressive Multiple Sclerosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.